DFTX logo

DFTX Definium Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$30.16
-1.92 (-5.99%)

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD…

Market Cap: $4.13Bdefiniumtx.com

Price

No data yet.

Social Signal Score

43
5d
40
1 mentions
—
30d
42
9 mentions
—
60d
43
12 mentions
—
90d
48
23 mentions
—
news: 14 · rss: 9

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 0Sell 0Strong Sell 0
Avg price target$67.45+123.6%
Low $52Median $68High $79
Current Consensus

Revenue

$0.00
$0.00
Nov 2016Sep 2026

Analyst Estimates

FY2025
$-2.00
$-2.13–$-1.80
7 analysts
FY2026
$-2.97
$-3.50–$-2.33
12 analysts
FY2027
$-1.95
$-2.46–$-1.58
12 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert Barrow
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
2.21
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
22.29
definiumtx.com